Literature DB >> 3259608

The effect of cyclosporine on epidermal cells. I. Cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro.

M Furue1, S I Katz.   

Abstract

Although the precise mechanism of action of cyclosporine (CS) is unknown, there is substantial evidence that CS preferentially acts on T cells by impairing lymphokine production. Recent studies have demonstrated that CS may also inhibit the functions of accessory cells and APC. Since topically applied CS inhibits contact sensitivity and epidermal Langerhans cells (LC) are very effective accessory cells and APC, we determined whether CS directly affects their accessory cell functions. Murine LC were pulsed with solvent control or with various doses of CS (up to 10 micrograms/ml) and then Con A-induced T cell proliferation was assayed. CS pulsing of LC caused, when compared with solvent control-pulsed LC, a dose-dependent decrease in T cell stimulation (up to 93%). LC fixed with paraformaldehyde after 2-h CS pulsing showed a similar degree of decreased accessory cell function, indicating that the immunosuppressive action is established by 2 h. The inhibitory capacity of CS pulsing on LC is not likely to be related to diminished IL-1 production, enhanced PG biosynthesis, or decreased surface Ia Ag intensity. The possibility of carryover of CS into the culture supernatants was ruled out by adding CS-pulsed LC or their supernatants to other T cell proliferative assays. Thus, these studies indicate that CS directly inhibits accessory cell functions of LC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259608

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Lack of demonstrable effect of cyclosporin A on human epidermal Langerhans cell function.

Authors:  J Péguet-Navarro; M Slaats; J Thivolet
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

2.  Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.

Authors:  A Horroccks; A D Ormerod; J I Duncan; A W Thomson
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity.

Authors:  G P Geba; W Ptak; P W Askenase
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

4.  Susceptible responsiveness to bacterial superantigens in peripheral blood mononuclear cells from patients with psoriasis.

Authors:  R Yokote; Y Tokura; F Furukawa; M Takigawa
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 5.  The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases.

Authors:  Yune-Jung Park; Seung-Ah Yoo; Mingyo Kim; Wan-Uk Kim
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.